GlobalData on MSN1d
Genentech wins FDA approval for second stroke treatmentGenentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...
The FDA has approved TNKase, a tissue plasminogen, clot-dissolving agent, to treat acute ischemic stroke in adults, according ...
Roche’s Genentech unit has received approval from the US Food and Drug Administration (FDA) for TNKase (tenecteplase) in ...
The FDA has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke (AIS) in ...
Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...
According to Roche subsidiary Genentech, which announced the label expansion on Monday, TNKase is the first new drug for ...
The US Food and Drug Administration has approved Tenecteplase as first FDA-approved stroke medication in nearly three decades ...
Genentech, part of the Roche (ROG SIX) group, has received a new approval from the US Food and Drug Administration for TNKase ...
Genentech announced that the U.S. Food and Drug Administration has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment ...
The approval was supported by data from the registry-linked, parallel group, open-label, randomized AcT trial, which compared tenecteplase to alteplase.
In 2023, Roche said it was removing TNKase for stroke from its phase 3 programmes after a readout of the TIMELESS trial, but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback